title: Pulmonary mucormycosis: what is the best strategy for therapy?
authors.affiliation: Division of Pulmonary Diseases and Critical Care, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA. Jfelipefernandez@hotmail.com
authors.forename: Juan F
authors.initials: JF
authors.lastname: Fernandez
authors.forename: Diego J
authors.initials: DJ
authors.lastname: Maselli
authors.forename: Tamara
authors.initials: T
authors.lastname: Simpson
authors.forename: Marcos I
authors.initials: MI
authors.lastname: Restrepo
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced; D000328:Adult; D000666:Amphotericin B / Q000009:adverse effects; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003646:Debridement; D054714:Echinocandins / Q000627:therapeutic use; D006801:Humans; D055666:Lipopeptides / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D000077551:Micafungin; D009091:Mucormycosis / Q000175:diagnosis / Q000628:therapy*; D011013:Pneumonectomy; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D014230:Triazoles; C101425:posaconazole; D000666:Amphotericin B; D000077551:Micafungin